| [1] |
Waks AG, Winer EP. Breast cancer treatment: a review[J]. JAMA, 2019, 321(3):288-300.
|
| [2] |
Li J, Yu K, Pang D, et al. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio, 2019 [2019-12-11]．
URL
|
| [3] |
Mackelenbergh MV, Seither F, Möbus V, et al. Effects of capecitabine as part of neo-/adjuvant chemotherapy. A meta-analysis of individual patient data from 12 randomized trials including 15，457 patients [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio，2019 [2019-12-11].
URL
|
| [4] |
Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer[J]. N Engl J Med, 2018, 379(22):2108-2121.
|
| [5] |
Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial[EB/OL]. [2020-02-13].
URL
|
| [6] |
Schmid P, Park YH, Ferreira M, et al. KEYNOTE-522 study of neoadjuvant pembrolizumab ＋ chemotherapy vs placebo ＋ chemotherapy, followed by adjuvant pembrolizumab vs placebo for early triple-negative breast cancer: pathologic complete response in key subgroups and by treatment exposure, residual cancer burden, and breast-conserving surgery [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio，2019 [2019-12-12].
URL
|
| [7] |
Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio，2019 [2019-12-12].
URL
|
| [8] |
Ogiya R, Niikura N, Kumaki N, et al. Comparison of tumor－infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients[J]. Cancer Sci, 2016, 107(12):1730-1735.
|
| [9] |
Loibl S, Untch M, Burchardi N, et al. A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study[J]. Ann Oncol 2019, 30(8):1279-1288.
|
| [10] |
Pusztai L, Reisenbichler E, Bai Y, et al. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC)[C/OL]// The San Antonio Breast Cancer Symposium, San Antonio，2019 [2019-12-11].
URL
|
| [11] |
Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta－analysis of randomized clinical trials[J]. J Clin Oncol, 2011, 29(16):2144-2149.
|
| [12] |
Wu J, Waxman DJ. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy[J]. Cancer Lett, 2018, 419:210-221.
|
| [13] |
Dalenc F, Garberis I, Filleron T, et al. Durvalumab compared to maintenance chemotherapy in patients with metastatic breast cancer: Results from phase Ⅱ randomized trial SAFIR02-IMMUNO [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio, 2019 [2019-12-12].
URL
|
| [14] |
Han H, Diab S, Alemany C, et al. Open label phase 1b/2 study of ladiratuzumab vedotin in combination with pembrolizumab for first-line treatment of patients with unresectable locally-advanced or metastatic triple-negative breast cancer [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio, 2019 [2019-12-11].
URL
|
| [15] |
Tolaney S, Blum J, Bondarenko I, et al. CONTESSA TRIO: A multinational, multicenter, phase 2 study of tesetaxel plus 3 different PD-(L)1 inhibitors in patients with metastatic triple-negative breast cancer (TNBC) and tesetaxel monotherapy in elderly patients with HER2- metastatic breast cancer (MBC) [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio, 2019 [2019-12-11].
URL
|
| [16] |
Krop I, Masuda N, Kogawa T, et al. Phase 1/2 first-in-human study of U3-1402, an anti-human epidermal growth factor receptor 3 (HER3) antibody-drug conjugate, in HER3-expressing advanced/unresectable or metastatic breast cancer, including those with triple negative breast cancer (TNBC) or HER3-low disease [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio, 2019 [2019-12-11].
URL
|
| [17] |
Rugo H, Chow LW, Cortes J, et al. Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio, 2019 [2019-12-11].
URL
|
| [18] |
Schmid P, Abraham J, Chan S, et al. Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial[J]. J Clin Oncol, 2020, 38(5):423-433.
|
| [19] |
Schmid P, Cortes J, Robson M, et al. Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase Ⅲ trial (CAPItello-290) [C/OL]// The San Antonio Breast Cancer Symposium, San Antonio, 2019[2019-12-12].
URL
|